Silodyx
Highly selective alpha-1A adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia (BPH) in adult men
Silodyx contains the active substance silodosin and is used to treat the signs and symptoms of benign prostatic hyperplasia (BPH) — an enlarged, non-cancerous prostate gland — in adult men. Silodosin is a highly selective alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate, bladder base, and urethra, improving urinary flow and easing symptoms such as weak stream, hesitancy, incomplete bladder emptying, urgency, and frequent urination. This page provides comprehensive, evidence-based information about Silodyx, including its correct dosage, potential side effects, drug interactions, contraindications, and important safety warnings.
Quick Facts
Key Takeaways
- Silodyx (silodosin) is a highly uroselective alpha-1A blocker used to treat moderate to severe urinary symptoms of benign prostatic hyperplasia (BPH) in adult men.
- The usual adult dose is 8 mg once daily taken with food; for moderate kidney impairment (creatinine clearance 30–50 mL/min), the starting dose is 4 mg once daily.
- Retrograde ejaculation (semen passing backwards into the bladder during orgasm) affects roughly 1 in 4 men taking silodosin — it is harmless and reversible but can impact fertility.
- Silodosin is contraindicated with strong CYP3A4 inhibitors (ritonavir, itraconazole, ketoconazole) and in severe liver or kidney impairment.
- Always inform eye surgeons before cataract or glaucoma surgery, as silodosin may cause Intraoperative Floppy Iris Syndrome (IFIS) even after stopping the medicine.
What Is Silodyx and What Is It Used For?
Silodyx belongs to a therapeutic class known as alpha-1 adrenergic receptor antagonists, commonly referred to as alpha-blockers. Unlike older members of this class (such as doxazosin or terazosin), silodosin demonstrates an unusually high degree of selectivity for the alpha-1A receptor subtype over alpha-1B and alpha-1D subtypes — approximately 162-fold greater binding affinity for alpha-1A. Because alpha-1A receptors are densely concentrated in the human prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra, silodosin exerts most of its pharmacological effect exactly where it is needed, with relatively little action on the alpha-1B receptors that regulate blood pressure in arterial smooth muscle.
This uroselectivity is clinically significant. Non-selective alpha-blockers can cause clinically important drops in blood pressure, postural dizziness, and syncope (fainting), particularly when treatment is first initiated or the dose is increased. Silodosin, by contrast, tends to produce fewer cardiovascular side effects, making it a useful option for men in whom blood-pressure-related adverse events must be minimized — for example, older patients, those with borderline blood pressure, or those already on antihypertensive therapy.
Benign prostatic hyperplasia (BPH) is one of the most common conditions affecting men as they age. By the age of 60, histological evidence of prostatic enlargement is present in over half of men, and by the age of 85 the proportion exceeds 80%. The prostate gland sits immediately below the bladder and surrounds the uppermost portion of the urethra (the tube through which urine leaves the body). As the gland enlarges, it compresses the urethra and contributes to obstruction of urinary flow. This mechanical obstruction combines with increased smooth muscle tone in the bladder neck and prostate to produce a constellation of symptoms collectively known as lower urinary tract symptoms (LUTS).
LUTS are usually divided into three categories. Voiding (obstructive) symptoms include hesitancy (difficulty starting urination), a weak or interrupted urinary stream, straining to void, prolonged voiding, terminal dribbling, and a sensation of incomplete bladder emptying. Storage (irritative) symptoms include urinary frequency, urgency, nocturia (waking at night to urinate), and occasionally urge incontinence. Post-micturition symptoms include post-void dribbling and persistent sensation of residual urine. These symptoms can profoundly affect quality of life, sleep, work performance, and emotional wellbeing.
The European Association of Urology (EAU) guidelines, the American Urological Association (AUA) guidelines, and NICE recommendations all position alpha-1 blockers as first-line pharmacological therapy for moderate to severe LUTS attributable to BPH. Multiple randomized controlled trials and meta-analyses have demonstrated that silodosin 8 mg once daily produces statistically and clinically significant improvements in the International Prostate Symptom Score (IPSS), the maximum urinary flow rate (Qmax), and quality-of-life scores compared with placebo. The onset of symptom relief is rapid: many men report improvement within two to three days, and most studies show near-maximal benefit by the end of the first week of treatment.
It is important to understand that silodosin does not reduce the physical size of the prostate gland. Unlike 5-alpha reductase inhibitors (such as finasteride or dutasteride), which work by blocking the conversion of testosterone to dihydrotestosterone and thereby shrinking glandular tissue over several months, alpha-blockers produce symptomatic relief by relaxing smooth muscle. For men with very large prostates or rapid disease progression, a urologist may recommend combination therapy with both an alpha-blocker and a 5-alpha reductase inhibitor. Silodyx does not cure BPH and does not remove the need for long-term follow-up: prostate size, prostate-specific antigen (PSA), and symptom progression should continue to be monitored.
Silodyx is available as hard capsules containing 4 mg of silodosin. Depending on the national market, capsules of 8 mg strength may also be available under the same or related brand names (such as Urorec in some European countries and Rapaflo in the United States). Silodosin is not approved for use in women or children; clinical trials have only been conducted in adult male populations. Always consult a healthcare professional if your symptoms do not improve within a few weeks of starting Silodyx, or if they worsen at any time during treatment.
What Should You Know Before Taking Silodyx?
Contraindications
There are several clinical situations in which Silodyx must not be used. You should not take this medicine if any of the following apply:
- Hypersensitivity: If you have a known allergy to silodosin or to any of the excipients listed in the composition section. Signs of an allergic reaction include rash, hives, itching, swelling of the face, lips, tongue, or throat, and breathing difficulty.
- Severe hepatic impairment: Patients with severe liver dysfunction (Child-Pugh class C) should not take Silodyx. Silodosin is extensively metabolized by the liver, and severe impairment can lead to markedly elevated blood concentrations and toxicity.
- Severe renal impairment: Silodyx is contraindicated in patients with severe kidney impairment (creatinine clearance <30 mL/min), because silodosin and its active metabolite KMD-3213G accumulate to potentially unsafe levels.
- Concurrent use of strong CYP3A4 inhibitors: Do not take Silodyx together with strong inhibitors of the liver enzyme CYP3A4, such as ritonavir (alone or in combination with ombitasvir/paritaprevir, lopinavir, or nirmatrelvir), ketoconazole, itraconazole, voriconazole, or clarithromycin. These drugs can increase silodosin plasma concentrations several-fold, dramatically raising the risk of dizziness and hypotension.
Warnings and Precautions
Speak to your doctor or pharmacist before starting Silodyx if any of the following apply to you:
- Orthostatic hypotension: Silodosin can cause a reduction in blood pressure, particularly when standing up from a sitting or lying position. Although this effect is less marked than with non-selective alpha-blockers, it still occurs. Patients with a history of postural dizziness or syncope should be monitored particularly carefully at the start of treatment.
- Moderate renal impairment: For patients with a creatinine clearance of 30 to 50 mL/min, treatment should begin at a reduced dose of 4 mg once daily. If well tolerated after one week, the dose may be cautiously increased to 8 mg once daily under medical supervision.
- Moderate hepatic impairment: Data are limited. Silodyx should be used with caution; close clinical monitoring is advised.
- Cataract or glaucoma surgery: Alpha-1A blockers, including silodosin, have been associated with Intraoperative Floppy Iris Syndrome (IFIS), a complication of eye surgery in which the iris does not dilate properly and may become floppy. Always inform your ophthalmologist that you take or have recently taken Silodyx.
- Prostate cancer screening: BPH and prostate cancer can cause similar urinary symptoms and may coexist. Your doctor may perform a digital rectal examination (DRE) and check serum PSA levels before starting treatment, and periodically thereafter, to rule out or monitor for prostate cancer. Silodosin does not typically alter PSA measurements.
- Cardiovascular disease: Patients with unstable angina, recent myocardial infarction, or severe heart failure should be evaluated carefully before starting silodosin, because blood pressure changes could have adverse consequences.
In some patients, particularly those concurrently taking blood pressure-lowering medications or PDE5 inhibitors (such as sildenafil, tadalafil, or vardenafil), Silodyx may cause dizziness, lightheadedness, or weakness within a few hours of the first dose. If this occurs, lie down immediately until the symptoms completely resolve. Rise slowly from sitting or lying positions for the first week of treatment. Contact your doctor if symptoms persist or are severe.
In rare cases, alpha-1 blockers including silodosin can cause priapism — a prolonged, often painful erection lasting longer than four hours and unrelated to sexual activity. Priapism is a urological emergency; if untreated, it can result in permanent erectile dysfunction or scarring of the penile tissue. If you experience an erection lasting more than four hours, seek emergency medical care immediately.
Ejaculatory Disorders and Fertility
Silodosin very commonly causes retrograde ejaculation, in which semen is redirected backwards into the bladder during orgasm rather than being expelled through the urethra. This occurs because the same alpha-1A receptors that silodosin blocks in the prostate are also densely expressed in the bladder neck and seminal vesicles, which normally contract to direct semen outwards during ejaculation. In clinical trials, ejaculatory disorder (most commonly reduced or absent ejaculate volume) was reported by 20 to 28% of men taking silodosin, compared with less than 1% on placebo.
Retrograde ejaculation is not harmful: the redirected semen is voided during the next urination and does not damage the bladder, kidneys, or reproductive organs. The sensation of orgasm is preserved. However, men who wish to father children should be aware that retrograde ejaculation can affect fertility by reducing the volume of ejaculate delivered during intercourse. If you are planning a family, discuss this with your doctor before starting Silodyx; alternative treatment options or assisted reproductive techniques may be considered. The effect is fully reversible once the medication is stopped.
Before Surgery
If you are scheduled for any surgery, tell your anesthesiologist and surgeon that you are taking Silodyx. This is especially important before cataract surgery or glaucoma surgery. The Intraoperative Floppy Iris Syndrome (IFIS) described above can still occur even weeks or months after silodosin has been stopped, so always disclose recent use. When the ophthalmologist is informed in advance, they can use pupil-expansion devices (iris rings or hooks), intracameral alpha-agonists such as phenylephrine, or modified phacoemulsification techniques to complete the surgery safely.
Pregnancy and Breastfeeding
Silodyx is intended for use in adult men only. It is not indicated for use in women and has not been studied in pregnant or breastfeeding populations. There is no reason for women to take this medicine. If a female partner accidentally ingests silodosin, she should contact a healthcare professional for advice. Men taking Silodyx who wish to conceive should note the effect on ejaculate volume described above.
Driving and Operating Machinery
Silodosin can cause dizziness, lightheadedness, drowsiness, and blurred vision, particularly at the beginning of treatment. Until you know how Silodyx affects you, do not drive a vehicle, operate heavy machinery, work at heights, or undertake any activity where sudden dizziness could lead to injury. Personal responsibility for fitness to drive applies; discuss any concerns with your doctor or pharmacist.
Silodyx should be taken with food (for example, with breakfast). Food reduces the peak plasma concentration of silodosin by about 25% and the total exposure by about 5%, which lowers the likelihood of dizziness while still maintaining therapeutic effect. Taking the capsule at roughly the same time every day helps maintain stable blood levels.
How Does Silodyx Interact with Other Drugs?
Drug interactions are a particularly important consideration with silodosin because the medicine is extensively metabolized by the liver enzyme CYP3A4, with additional contributions from alcohol dehydrogenase and UGT2B7. Drugs that inhibit CYP3A4 can raise silodosin plasma levels substantially, while inducers may reduce its effectiveness. Silodosin is also a substrate of the drug transporter P-glycoprotein. Always provide your doctor and pharmacist with a complete list of all prescription medicines, over-the-counter products, and herbal or dietary supplements you are taking.
Major Interactions — Do Not Combine
| Drug / Class | Examples | Clinical Risk |
|---|---|---|
| Strong CYP3A4 inhibitors | Ketoconazole (oral), itraconazole, voriconazole, posaconazole, ritonavir, cobicistat, clarithromycin, telithromycin | 3–4 fold increase in silodosin exposure; risk of severe dizziness, orthostatic hypotension, and syncope |
| Other alpha-1 blockers | Tamsulosin, alfuzosin, doxazosin, terazosin, prazosin, indoramin, phenoxybenzamine | Additive vasodilation; severe hypotension, fainting, cardiovascular collapse |
| HIV protease inhibitors | Ritonavir, lopinavir/ritonavir, atazanavir/cobicistat, darunavir/cobicistat, nirmatrelvir/ritonavir (Paxlovid) | Marked CYP3A4 inhibition; dangerous elevation of silodosin levels |
Moderate Interactions — Use with Caution
| Drug / Class | Examples | Clinical Risk |
|---|---|---|
| Moderate CYP3A4 inhibitors | Diltiazem, verapamil, erythromycin, fluconazole, aprepitant, grapefruit juice | Moderate increase in silodosin exposure; enhanced side effects |
| PDE5 inhibitors | Sildenafil, tadalafil, vardenafil, avanafil | Additive blood-pressure-lowering effect; start PDE5 inhibitor at lowest dose and monitor |
| Antihypertensive agents | ACE inhibitors, ARBs, calcium-channel blockers, beta-blockers, diuretics, central alpha-agonists | Additive hypotension; monitor blood pressure, especially when initiating therapy |
| Nitrates | Nitroglycerin, isosorbide mononitrate, isosorbide dinitrate | Pronounced vasodilation; risk of orthostatic hypotension |
| CYP3A4 inducers | Rifampicin, rifabutin, phenytoin, carbamazepine, phenobarbital, St. John’s wort, efavirenz | Reduced silodosin exposure; loss of therapeutic effect |
| P-glycoprotein inhibitors | Ciclosporin, quinidine, amiodarone | Potential increase in silodosin exposure |
| QT-prolonging drugs | Class Ia and III antiarrhythmics, certain antipsychotics, fluoroquinolones, methadone | Theoretical risk of arrhythmia; ECG monitoring in high-risk patients |
| Digoxin | Digoxin | No clinically significant pharmacokinetic interaction; no dose adjustment required |
Food, Alcohol, and Lifestyle
Food: Silodyx should always be taken with food. Taking the capsule on an empty stomach increases the maximum plasma concentration (Cmax) and may increase the risk of dizziness or hypotension. Grapefruit and grapefruit juice can inhibit intestinal CYP3A4 and may raise silodosin levels; it is prudent to avoid regular grapefruit consumption while on therapy.
Alcohol: Alcohol can lower blood pressure and enhance the hypotensive effect of silodosin. Drink alcohol in moderation, and be particularly cautious in the first week of treatment or after any dose change.
What Is the Correct Dosage of Silodyx?
Always take Silodyx exactly as your doctor has prescribed. Read the patient information leaflet that comes with your medicine, and ask your pharmacist if you are unsure about any aspect of your treatment. Silodyx is supplied as hard capsules containing 4 mg of silodosin; the standard adult dose of 8 mg once daily is therefore achieved by taking two 4 mg capsules together at the same time. In some countries, an 8 mg capsule strength is also marketed for convenience.
Adults
Standard Adult Dose
8 mg once daily (two 4 mg capsules), taken with food at approximately the same time each day. Swallow the capsules whole with a full glass of water. Do not open, crush, or chew the capsules, as this may alter how the medicine is released. Most patients notice symptom improvement within the first one to two weeks of treatment.
Elderly Patients (Over 65 Years)
Elderly Dose
8 mg once daily — no routine dose adjustment is required on the basis of age alone. However, older adults are more likely to have reduced kidney or liver function, take multiple medications, and be susceptible to orthostatic hypotension, so particular clinical caution is recommended, especially during initiation.
Patients with Kidney (Renal) Impairment
Mild Renal Impairment (CrCl >50 mL/min)
8 mg once daily — no dose adjustment required.
Moderate Renal Impairment (CrCl 30–50 mL/min)
Start at 4 mg once daily. If the lower dose is well tolerated after one week, the dose may be increased cautiously to 8 mg once daily under medical supervision. Plasma concentrations of silodosin and its active metabolite can be up to three times higher in this group, increasing the risk of hypotension.
Severe Renal Impairment (CrCl <30 mL/min)
Contraindicated. Silodyx should not be used in patients with severe kidney impairment, including those on dialysis, because safe dosing has not been established and drug accumulation is substantial.
Patients with Liver (Hepatic) Impairment
Mild to Moderate Hepatic Impairment
8 mg once daily with careful monitoring in mild impairment. In moderate impairment (Child-Pugh class B), use with caution; no formal dose recommendation is available due to limited data.
Severe Hepatic Impairment (Child-Pugh C)
Contraindicated. Silodyx is not recommended and should not be prescribed in severe liver disease.
Children and Adolescents
Silodyx is not recommended for use in children or adolescents under 18 years of age. Benign prostatic hyperplasia is a disease of older adult men; there is no relevant indication for silodosin in the pediatric population, and no safety or efficacy data exist.
Women
Silodyx is not indicated for women. The medicine is designed for a male-specific condition.
| Patient Group | Starting Dose | Frequency | Notes |
|---|---|---|---|
| Adult men | 8 mg | Once daily | Take with food, same time each day |
| Elderly (>65 years) | 8 mg | Once daily | No routine adjustment; monitor blood pressure |
| Mild renal impairment | 8 mg | Once daily | No adjustment needed |
| Moderate renal impairment (CrCl 30–50) | 4 mg | Once daily | Titrate to 8 mg after 1 week if tolerated |
| Severe renal impairment (CrCl <30) | N/A | N/A | Contraindicated |
| Severe hepatic impairment (Child-Pugh C) | N/A | N/A | Contraindicated |
| Children (<18 years) | N/A | N/A | Not recommended; no data available |
| Women | N/A | N/A | Not indicated |
Missed Dose
If you forget a dose of Silodyx, take it with food as soon as you remember on the same day. If it is nearly time for your next scheduled dose, skip the missed dose and continue with your normal schedule. Do not take a double dose to make up for a missed one — doing so increases the risk of dizziness, hypotension, and other adverse effects.
Overdose
If you take more Silodyx than prescribed, or if a child accidentally ingests the medicine, contact your local poison control center or emergency services immediately. Symptoms of overdose include marked dizziness, severe hypotension (very low blood pressure), rapid heart rate, and fainting. Lie flat on your back to help maintain blood flow to the brain. Do not attempt to drive yourself to hospital. Management is supportive: there is no specific antidote, but dialysis is unlikely to be effective because silodosin is highly protein-bound.
Stopping Treatment
Continue to take Silodyx as prescribed even if your symptoms improve. BPH is a chronic condition, and symptoms typically return within days to weeks of stopping treatment. Do not discontinue the medicine without discussing it with your doctor. If you decide together that treatment should stop, silodosin does not require tapering — it can be discontinued abruptly without rebound effects. Any additional questions about the duration of treatment should be directed to your urologist or general practitioner.
What Are the Side Effects of Silodyx?
Like all medicines, Silodyx can cause side effects, although not everyone experiences them. Most side effects are mild to moderate in intensity, begin within the first week of treatment, and either resolve spontaneously or remain stable over time. Side effects are classified below according to the MedDRA frequency convention used by the European Medicines Agency and most national regulators.
- Severe allergic reaction (anaphylaxis or angioedema): swelling of the face, lips, tongue, or throat; difficulty breathing or swallowing; widespread rash or hives.
- Priapism: a painful erection lasting more than four hours and not related to sexual activity. This is a urological emergency.
- Syncope (fainting) or severe dizziness: especially if accompanied by chest pain or palpitations.
- Signs of severe liver problems: yellowing of the skin or whites of the eyes (jaundice), dark urine, persistent nausea, right upper abdominal pain.
Very Common
May affect more than 1 in 10 people
- Ejaculation disorder (mainly retrograde ejaculation; reduced or absent semen volume during orgasm) — occurs in approximately 20–28% of users
Common
May affect up to 1 in 10 people
- Dizziness
- Orthostatic hypotension (lightheadedness on standing)
- Nasal congestion (stuffy or runny nose)
- Diarrhoea
- Headache
- Reduced libido (decreased sexual desire)
Uncommon
May affect up to 1 in 100 people
- Palpitations or rapid heartbeat (tachycardia)
- Somnolence (drowsiness)
- Dry mouth
- Nausea
- Rash, pruritus (itching), or urticaria (hives)
- Erectile dysfunction
- Syncope (fainting), including loss of consciousness on standing
- Elevated liver enzymes on blood testing
Rare
May affect up to 1 in 1,000 people
- Tachyarrhythmia (abnormal heart rhythm)
- Angioedema (deep tissue swelling of face, lips, tongue)
- Drug hypersensitivity reaction
Frequency Not Known
Cannot be estimated from available data
- Priapism (prolonged, painful erection)
- Intraoperative Floppy Iris Syndrome (IFIS) during cataract or glaucoma surgery
- Hepatic injury (rare cases of elevated liver enzymes or jaundice)
- Hypersensitivity reactions including facial swelling and tongue swelling
Managing Common Side Effects
Dizziness and orthostatic hypotension are most likely in the first week of treatment. Rise slowly from sitting or lying positions; sit on the edge of the bed for a moment before standing. Avoid alcohol, hot showers, and prolonged standing for the first few days. If symptoms persist beyond two weeks, or if you faint, contact your doctor — a dose reduction or change in medication may be needed.
Retrograde ejaculation is predictable, expected, and reversible. The typical patient will notice a much smaller volume of ejaculate, or no visible ejaculate at all, despite normal orgasm. The semen passes into the bladder and is voided with the next urination, which may appear slightly cloudy. This effect is not associated with any health risk, but it can reduce fertility. Men who do not wish to experience this side effect should discuss alternatives with their doctor.
Nasal congestion may be persistent but is generally mild. Saline nasal sprays can help; decongestant nasal sprays should only be used short-term and are not recommended as routine treatment while on silodosin.
Cataract Surgery and Intraoperative Floppy Iris Syndrome
Silodosin's high selectivity for alpha-1A receptors — which are also present in the iris dilator muscle — means that it carries a particularly notable risk of Intraoperative Floppy Iris Syndrome (IFIS). In IFIS, the iris billows or prolapses during surgery, the pupil constricts progressively even after pharmacological dilation, and complications such as iris trauma or vitreous loss can occur. The risk persists even after stopping silodosin, because the drug appears to alter the structural tone of the iris dilator muscle. Always inform any ophthalmologist planning intraocular surgery that you take or have ever taken Silodyx. Forewarned surgeons can prevent IFIS-related complications almost entirely by using modern techniques.
Reporting Side Effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed on this page. You can also report side effects directly to your national medicines regulatory authority. In the United Kingdom, report through the MHRA Yellow Card Scheme. In the United States, report to the FDA MedWatch program. In the European Union, report through the national pharmacovigilance system of your country. By reporting side effects, you help improve the safety information available for this medicine.
How Should You Store Silodyx?
Proper storage helps ensure that Silodyx remains effective and safe until it is used. Follow the guidance below carefully.
- Temperature: Store below 30°C (86°F). Silodyx does not require refrigeration. Avoid exposing the capsules to direct sunlight, high humidity, or temperature extremes.
- Original packaging: Keep the capsules in their original blister pack and outer carton until you are ready to take them. The packaging protects against light and moisture, which can degrade the medicine.
- Location: A cool, dry place such as a bedroom drawer or kitchen cabinet away from the stove, sink, and windows is usually suitable. Do not store Silodyx in a bathroom cabinet, where humidity is typically high.
- Keep out of reach of children: Store the medicine where children and pets cannot access it. Accidental ingestion of silodosin by a child or woman could cause dangerous blood pressure effects.
- Check the expiry date: The expiry date (EXP) is printed on both the blister foil and the outer carton. The date refers to the last day of the stated month. Do not use Silodyx after the expiry date.
- Do not use damaged medicines: If the blister is torn, the capsules look discolored, or there is any visible sign of damage or contamination, do not take the medicine. Consult your pharmacist.
- Safe disposal: Do not throw medicines away in household waste, wastewater, or toilets. Return unused or expired Silodyx to your local pharmacy for environmentally responsible disposal. These measures help protect the environment and prevent misuse.
What Does Silodyx Contain?
Knowing the complete composition of your medicine is useful, particularly if you have allergies, intolerances, or dietary restrictions (for example, a need to avoid gluten, lactose, or animal-derived ingredients).
Active Ingredient
Each hard capsule contains 4 mg of silodosin, the therapeutically active substance responsible for the medicine’s clinical effect.
Inactive Ingredients (Excipients)
Capsule contents: pregelatinized maize starch, mannitol (E421), magnesium stearate, and sodium lauryl sulfate.
Capsule shell: gelatin and titanium dioxide (E171), giving the capsule a characteristic white or off-white appearance.
Printing ink (if applicable): varies by manufacturer and batch; commonly includes shellac and iron oxide.
Excipient Warnings
Silodyx is generally well tolerated, but patients with rare inherited problems of fructose intolerance should note that mannitol, although poorly absorbed, is derived from fructose metabolism. There is no lactose in the standard formulation. The capsule shell contains gelatin, which is animal-derived; this medicine is therefore not suitable for patients following a strict vegan diet and may raise considerations for some religious observances.
Appearance and Pack Sizes
Silodyx 4 mg hard capsules are supplied as opaque white to off-white gelatin capsules. The capsules are usually marked with identifying characters (for example, “SILO 4”) printed on the body or cap. Typical pack sizes include blister packs of 10, 20, 30, 50, 90, and 100 capsules. Not all pack sizes may be marketed in every country.
Frequently Asked Questions About Silodyx
Silodyx (silodosin) is used to treat the signs and symptoms of benign prostatic hyperplasia (BPH) in adult men, commonly known as an enlarged prostate. It belongs to a class of medicines called highly selective alpha-1A adrenergic receptor antagonists. By blocking alpha-1A receptors in the prostate and bladder neck, silodosin relaxes smooth muscle and improves urinary flow. It does not shrink the prostate but relieves urinary symptoms such as weak stream, hesitancy, incomplete bladder emptying, urinary urgency, and increased frequency of urination, including nighttime waking.
The usual adult dose is 8 mg once daily (two 4 mg Silodyx capsules or one 8 mg capsule, depending on strength availability in your country), taken with food at the same time each day. Swallow the capsule whole with water. Taking silodosin with food reduces the peak blood concentration and lowers the risk of dizziness while maintaining therapeutic effect. Patients with moderate kidney impairment (creatinine clearance 30 to 50 mL/min) should start at 4 mg once daily and may increase to 8 mg after a week if tolerated. Do not crush, open, or chew the capsules.
Silodosin is highly selective for alpha-1A adrenergic receptors, which are densely expressed not only in the prostate but also in the seminal vesicles, vas deferens, and bladder neck. Blocking these receptors during orgasm prevents the bladder neck from closing, allowing semen to flow backwards into the bladder rather than out through the urethra. This effect, known as retrograde ejaculation, occurs in approximately 20 to 28 percent of men taking silodosin — a higher frequency than with less-selective alpha-blockers such as tamsulosin or alfuzosin. It is not harmful, does not affect the sensation of orgasm, and is fully reversible when the medication is stopped. However, it can reduce fertility because less semen is delivered during intercourse.
The most common side effects of Silodyx are ejaculation disorders (mainly retrograde ejaculation, affecting roughly 1 in 4 men), dizziness, nasal congestion (stuffy nose), and diarrhoea. Less frequent side effects include headache, orthostatic hypotension (dizziness on standing), drowsiness, dry mouth, decreased libido, and in rare cases erectile dysfunction. Because silodosin is more selective for prostate-specific alpha-1A receptors than older alpha-blockers, it causes fewer cardiovascular side effects such as severe drops in blood pressure. Most side effects are mild and tend to appear early in treatment. Contact your doctor if side effects are severe, persistent, or concerning.
Silodyx can generally be taken with phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil (Viagra), tadalafil (Cialis), or vardenafil (Levitra), but caution is required because both medicines can lower blood pressure, increasing the risk of dizziness or fainting. Your doctor should start the PDE5 inhibitor at the lowest effective dose and monitor blood pressure carefully, particularly during the first few doses. Daily low-dose tadalafil (5 mg) used for both BPH and erectile dysfunction is not routinely combined with silodosin without specialist advice, because dual treatment of BPH with an alpha-blocker and daily tadalafil has not been well studied. Always inform your doctor about all erectile dysfunction treatments you use, including those bought online.
Alpha-1A blockers such as silodosin can cause Intraoperative Floppy Iris Syndrome (IFIS) during cataract and glaucoma surgery. In this condition, the iris becomes floppy, the pupil does not dilate adequately despite pharmacological drops, and surgical complications such as iris trauma or vitreous loss may occur. The risk is particularly well documented for highly selective alpha-1A blockers. If your ophthalmologist knows you are taking or have recently taken Silodyx, they can use modified surgical techniques, pupil-expansion devices (iris rings or hooks), or intracameral agents such as phenylephrine to manage IFIS safely. Even if you stopped silodosin weeks or months before surgery, the risk remains, so always disclose recent use to your eye surgeon.
Silodosin acts rapidly. Many men notice improvement in urinary flow and a reduction in symptoms within two to three days of starting treatment, and most report near-maximal benefit by the end of the first week. In clinical trials, significant improvements in the International Prostate Symptom Score (IPSS) and maximum urinary flow rate (Qmax) compared with placebo were observed within the first week and were maintained for the duration of treatment. If your symptoms do not improve after four to six weeks of consistent use, contact your doctor — a change of therapy or further investigation may be required.
References
- European Medicines Agency (EMA). Silodosin — Summary of Product Characteristics (Urorec/Silodyx). www.ema.europa.eu.
- Gravas S, Cornu JN, Gacci M, et al. EAU Guidelines on the Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology; 2024. uroweb.org/guidelines.
- Chapple CR, Montorsi F, Tammela TL, et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011;59(3):342–352. doi:10.1016/j.eururo.2010.10.046.
- Yoshida M, Homma Y, Kawabe K. Silodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs. 2007;16(12):1955–1965. doi:10.1517/13543784.16.12.1955.
- Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009;181(6):2634–2640. doi:10.1016/j.juro.2009.02.034.
- Joint Formulary Committee. British National Formulary (BNF). Silodosin monograph. bnf.nice.org.uk.
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List. Geneva: WHO; 2023. www.who.int.
- Chang DF, Campbell JR, Colin J, Schweitzer C. Prospective masked comparison of intraoperative floppy iris syndrome severity with tamsulosin versus alfuzosin. Ophthalmology. 2014;121(4):829–834. doi:10.1016/j.ophtha.2013.10.030.
- U.S. Food and Drug Administration (FDA). Rapaflo (silodosin) — Prescribing Information. www.accessdata.fda.gov.
- Novara G, Tubaro A, Sanseverino R, et al. Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement. World J Urol. 2013;31(4):997–1008. doi:10.1007/s00345-012-0944-8.
About Our Medical Editorial Team
Medical Review
This article has been reviewed by our Medical Review Board, consisting of board-certified specialists in urology and clinical pharmacology. All medical claims are supported by peer-reviewed research and aligned with current international guidelines from the EAU, EMA, WHO, and BNF. The information reflects regulatory summaries of product characteristics as of the last review date.
Editorial Standards
iMedic follows the GRADE evidence framework. All drug information is derived from approved product summaries, systematic reviews, randomized controlled trials, and clinical practice guidelines. We have no commercial funding and accept no pharmaceutical sponsorship. Content is updated when new safety signals, interaction data, or clinical evidence become available.
This article was first published on and was last medically reviewed on . Our editorial team reviews drug information at least annually or whenever new safety data become available.